Genoptix Medical Laboratory is a Carlsbad-headquartered clinical oncology laboratory on Rutherford Road that has specialized in hematopathology and solid tumor molecular profiling since its founding in 1999. More than 27,000 square feet of laboratory space and a staff exceeding 400 process bone marrow, blood, and lymph node specimens for community oncologists and pathologists nationwide, placing the facility within the same Carlsbad life-sciences corridor occupied by Ionis Pharmaceuticals. The COMPASS diagnostic platform integrates morphology review, flow cytometry, cytogenetics, fluorescence in situ hybridization, and molecular testing into a single comprehensive hematomalignancy workup. Next-generation sequencing panels based on clinically validated markers identify actionable mutations in non-small cell lung cancer and other solid tumors, guiding targeted therapy selection. An FDA-authorized BCR-ABL MRDx TFR Monitoring Test supports treatment-free remission decisions for chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy, a precision medicine tool that feeds into the broader oncologic care network anchored by providers such as Scripps Coastal Medical Center Carlsbad. Acquired by Novartis in 2011 for $470 million and subsequently returned to independent operation, the laboratory maintains CAP accreditation and CLIA certification for high-complexity testing across its full diagnostic menu.